FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892356278> ?p ?o ?g. }

• W2892356278 endingPage "9047" @default.
• W2892356278 startingPage "9047" @default.
• W2892356278 abstract "9047 Background: Atezo (anti–PD-L1) + bev (anti-VEGF) + chemo prolonged PFS vs bev + chemo in patients (pts) with 1L nonsquamous mNSCLC in the randomized, Phase III IMpower150 study. PRO data, including symptom burden, functioning and health-related quality of life (HRQoL), were evaluated to assess overall clinical benefit in each treatment (Tx) arm. Methods: Pts received atezo 1200 mg + carboplatin (C) AUC 6 + paclitaxel (P) 200 mg/m2 (Arm A) or atezo + bev 15 mg/kg + C + P (Arm B) vs bev + C + P (Arm C) IV q3w for 4 or 6 cycles per investigator decision, then maintenance atezo, atezo + bev, or bev, respectively. PRO data were collected using the EORTC QLQ-C30 and QLQ-LC13 questionnaires. Prespecified analyses included the mean change from baseline in symptoms, functioning and HRQoL and time to deterioration (TTD) in lung cancer symptoms. Clinically meaningful change was defined as a ≥10-point change in score from baseline. Results: PRO completion rates were high (≥70% through cycle 23 for all arms). Mean changes from baseline indicated that a clinically meaningful worsening (≥10-point change) was not observed in any arm through cycle 13 (≈25% of pts remain in Arm C); HRQoL and physical functioning scores minimally decreased (Arm A: −2.83 and −3.39; Arm B: −1.8 and −3.98; Arm C: −1.92 and −2.6) with concurrent numerical worsening in Tx-related symptom scores (e.g., fatigue, constipation, nausea/vomiting). Following chemo completion, scores returned to baseline or numerically improved. HRQoL, physical functioning and Tx-related symptoms were comparable between Arms B and C. No difference was observed between arms in the TTD in lung cancer symptoms assessed. All arms reported numerical improvement in multiple lung cancer symptoms while on Tx. Conclusions: These data suggest that prolonged PFS in Arm B was achieved without compromising HRQoL or physical functioning despite higher Tx-related AEs than Arm C. PRO data reflected a minimal Tx burden across arms, further reduced following chemo discontinuation. Overall, PRO data support the positive benefit:risk of the clinical data with atezo + bev + chemo in 1L nonsquamous mNSCLC. Clinical trial information: NCT02366143." @default.
• W2892356278 created "2018-09-27" @default.
• W2892356278 creator A5017742334 @default.
• W2892356278 creator A5025814906 @default.
• W2892356278 creator A5034169124 @default.
• W2892356278 creator A5040589443 @default.
• W2892356278 creator A5046728958 @default.
• W2892356278 creator A5051345950 @default.
• W2892356278 creator A5054996413 @default.
• W2892356278 creator A5072962574 @default.
• W2892356278 creator A5078389632 @default.
• W2892356278 creator A5078535728 @default.
• W2892356278 creator A5078629724 @default.
• W2892356278 date "2018-05-20" @default.
• W2892356278 modified "2023-10-14" @default.
• W2892356278 title "Patient-reported outcomes (PROs) in the randomized, phase III IMpower150 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous metastatic NSCLC (mNSCLC)." @default.
• W2892356278 doi "https://doi.org/10.1200/jco.2018.36.15_suppl.9047" @default.
• W2892356278 hasPublicationYear "2018" @default.
• W2892356278 type Work @default.
• W2892356278 sameAs 2892356278 @default.
• W2892356278 citedByCount "10" @default.
• W2892356278 countsByYear W28923562782019 @default.
• W2892356278 countsByYear W28923562782020 @default.
• W2892356278 countsByYear W28923562782021 @default.
• W2892356278 countsByYear W28923562782022 @default.
• W2892356278 countsByYear W28923562782023 @default.
• W2892356278 crossrefType "journal-article" @default.
• W2892356278 hasAuthorship W2892356278A5017742334 @default.
• W2892356278 hasAuthorship W2892356278A5025814906 @default.
• W2892356278 hasAuthorship W2892356278A5034169124 @default.
• W2892356278 hasAuthorship W2892356278A5040589443 @default.
• W2892356278 hasAuthorship W2892356278A5046728958 @default.
• W2892356278 hasAuthorship W2892356278A5051345950 @default.
• W2892356278 hasAuthorship W2892356278A5054996413 @default.
• W2892356278 hasAuthorship W2892356278A5072962574 @default.
• W2892356278 hasAuthorship W2892356278A5078389632 @default.
• W2892356278 hasAuthorship W2892356278A5078535728 @default.
• W2892356278 hasAuthorship W2892356278A5078629724 @default.
• W2892356278 hasConcept C121608353 @default.
• W2892356278 hasConcept C126322002 @default.
• W2892356278 hasConcept C143998085 @default.
• W2892356278 hasConcept C159110408 @default.
• W2892356278 hasConcept C168563851 @default.
• W2892356278 hasConcept C203092338 @default.
• W2892356278 hasConcept C2775949291 @default.
• W2892356278 hasConcept C2776694085 @default.
• W2892356278 hasConcept C2777701055 @default.
• W2892356278 hasConcept C2777802072 @default.
• W2892356278 hasConcept C2778239845 @default.
• W2892356278 hasConcept C2779951463 @default.
• W2892356278 hasConcept C2780030458 @default.
• W2892356278 hasConcept C2780580376 @default.
• W2892356278 hasConcept C2780852908 @default.
• W2892356278 hasConcept C2781451048 @default.
• W2892356278 hasConcept C71924100 @default.
• W2892356278 hasConceptScore W2892356278C121608353 @default.
• W2892356278 hasConceptScore W2892356278C126322002 @default.
• W2892356278 hasConceptScore W2892356278C143998085 @default.
• W2892356278 hasConceptScore W2892356278C159110408 @default.
• W2892356278 hasConceptScore W2892356278C168563851 @default.
• W2892356278 hasConceptScore W2892356278C203092338 @default.
• W2892356278 hasConceptScore W2892356278C2775949291 @default.
• W2892356278 hasConceptScore W2892356278C2776694085 @default.
• W2892356278 hasConceptScore W2892356278C2777701055 @default.
• W2892356278 hasConceptScore W2892356278C2777802072 @default.
• W2892356278 hasConceptScore W2892356278C2778239845 @default.
• W2892356278 hasConceptScore W2892356278C2779951463 @default.
• W2892356278 hasConceptScore W2892356278C2780030458 @default.
• W2892356278 hasConceptScore W2892356278C2780580376 @default.
• W2892356278 hasConceptScore W2892356278C2780852908 @default.
• W2892356278 hasConceptScore W2892356278C2781451048 @default.
• W2892356278 hasConceptScore W2892356278C71924100 @default.
• W2892356278 hasIssue "15_suppl" @default.
• W2892356278 hasLocation W28923562781 @default.
• W2892356278 hasOpenAccess W2892356278 @default.
• W2892356278 hasPrimaryLocation W28923562781 @default.
• W2892356278 hasRelatedWork W1969882220 @default.
• W2892356278 hasRelatedWork W1979960106 @default.
• W2892356278 hasRelatedWork W1981118621 @default.
• W2892356278 hasRelatedWork W2081557631 @default.
• W2892356278 hasRelatedWork W2111792237 @default.
• W2892356278 hasRelatedWork W2340223763 @default.
• W2892356278 hasRelatedWork W2377198612 @default.
• W2892356278 hasRelatedWork W2395882867 @default.
• W2892356278 hasRelatedWork W2399120251 @default.
• W2892356278 hasRelatedWork W3003421087 @default.
• W2892356278 hasVolume "36" @default.
• W2892356278 isParatext "false" @default.
• W2892356278 isRetracted "false" @default.
• W2892356278 magId "2892356278" @default.
• W2892356278 workType "article" @default.